GLS 010

Drug Profile

GLS 010

Alternative Names: GLS-010; WBP3055

Latest Information Update: 24 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator WuXi Biologics
  • Developer Arcus Biosciences; Harbin Gloria Pharmaceuticals; WuXi Biologics
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Programmed cell death-1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Cancer

Most Recent Events

  • 18 Aug 2017 Preclinical trials in Cancer in USA (Parenteral)
  • 17 Aug 2017 WuXi Biologics, Harbin Gloria Pharmaceuticals and Arcus Biosciences agree to co-promote and co-develop GLS 010 in North America, Europe, Japan and certain other territories for Cancer
  • 17 Aug 2017 Phase-I clinical trials in Cancer in China (Parenteral), before August 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top